Literature DB >> 33125170

Patient-reported outcomes collected in ambulatory oncology practices: Feasibility, patterns, and correlates.

Christopher R Friese1, Alex J Fauer2, Clare Kuisell3, Kari Mendelsohn-Victor4, Nathan C Wright4, Jennifer J Griggs5,6, Milisa Manojlovich7.   

Abstract

OBJECTIVE: To examine the feasibility of soliciting outcomes from adults who received chemotherapy treatment for cancer and describe the patterns and correlates of patient-reported toxicities. DATA SOURCES: Patient survey data from 29 Michigan ambulatory oncology practices collected in 2017. STUDY
DESIGN: Secondary analysis of patient survey data. Descriptive statistics were generated at the patient and practice levels. Thematic analysis of open-text comments identified clusters of frequently reported toxicities. DATA COLLECTION
METHODS: Patients completed 11 items from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. Using a 5-point Likert scale, patients rated the frequency of nausea, vomiting, diarrhea, and pain; the severity of nausea, vomiting, constipation, numbness/tingling, and pain; and how much numbness/tingling and pain interfered with usual or daily activities. Patients could also report two toxicities in open-text comments. Finally, patients reported unplanned health care service for toxicity or side effect management. PRINCIPAL
FINDINGS: Of 3565 eligible patients, 2245 participated (63%) and 457 (20%) rated at least one toxicity as severe/very severe. Across practices, the proportion of patients who reported at least one severe/very severe toxicity ranged from 8% to 50%. Troubling toxicities included pain frequency (mean 2.3, SD 1.3), pain severity (2.1, 1.1), and diarrhea frequency (1.9, 1.0). From completed assessments, 1653 (74%) reported at least one toxicity in open-text comments; fatigue (n = 182), stomach discomfort (n = 53), and skin/nail changes (n = 41) were most frequently reported. Regarding consequences, 156 patients (7%) reported unplanned health care service use: 41 (26%) visited an emergency department and 32 (21%) were admitted to a hospital.
CONCLUSIONS: Querying patients on chemotherapy treatment experiences and toxicities was feasible. Toxicity rates varied across practices, which informed quality improvement. Toxicity severity and service use incidence exceed previously published trial data, particularly for pain, fatigue, and gastrointestinal issues. Open-text questions enabled exploration with newer treatment regimens. © Health Research and Educational Trust.

Entities:  

Keywords:  ambulatory care; oncology; patient-reported outcome measures; quality of health care

Mesh:

Substances:

Year:  2020        PMID: 33125170      PMCID: PMC7704472          DOI: 10.1111/1475-6773.13574

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  26 in total

1.  PRO-cision Medicine: Personalizing Patient Care Using Patient-Reported Outcomes.

Authors:  Roxanne E Jensen; Claire F Snyder
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

2.  Automated monitoring of symptoms during ambulatory chemotherapy and oncology providers' use of the information: a randomized controlled clinical trial.

Authors:  Kathi H Mooney; Susan L Beck; Robert H Friedman; Ramesh Farzanfar; Bob Wong
Journal:  Support Care Cancer       Date:  2014-04-01       Impact factor: 3.603

3.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

Review 4.  The rationale for collecting patient-reported symptoms during routine chemotherapy.

Authors:  Ethan Basch
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

5.  Toxicity-Related Factors Associated With Use of Services Among Community Oncology Patients.

Authors:  Jordan M Harrison; Philip J Stella; Beth LaVasseur; Paul T Adams; Lauren Swafford; JoAnn Lewis; Kari Mendelsohn-Victor; Christopher R Friese
Journal:  J Oncol Pract       Date:  2016-07-12       Impact factor: 3.840

6.  Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.

Authors:  Ethan Basch; Alexia Iasonos; Tiffani McDonough; Allison Barz; Ann Culkin; Mark G Kris; Howard I Scher; Deborah Schrag
Journal:  Lancet Oncol       Date:  2006-11       Impact factor: 41.316

7.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

8.  Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Authors:  Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

9.  Impact of a Statewide Oral Oncolytic Initiative on Five Participating Practices.

Authors:  Emily Mackler; Gianni B Scappaticci; Teresa M Salgado; Laura Petersen; Emily J Davis; Emily Peltier; Jennifer J Griggs; Roy T Sabo; Karen B Farris
Journal:  J Oncol Pract       Date:  2018-04-11       Impact factor: 3.840

10.  Long-term effectiveness and cost-effectiveness of high versus low-to-moderate intensity resistance and endurance exercise interventions among cancer survivors.

Authors:  C S Kampshoff; J M van Dongen; W van Mechelen; G Schep; A Vreugdenhil; J W R Twisk; J E Bosmans; J Brug; M J M Chinapaw; Laurien M Buffart
Journal:  J Cancer Surviv       Date:  2018-03-01       Impact factor: 4.442

View more
  1 in total

1.  Patient-reported outcomes collected in ambulatory oncology practices: Feasibility, patterns, and correlates.

Authors:  Christopher R Friese; Alex J Fauer; Clare Kuisell; Kari Mendelsohn-Victor; Nathan C Wright; Jennifer J Griggs; Milisa Manojlovich
Journal:  Health Serv Res       Date:  2020-10-30       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.